Work

Safety and efficacy of nivolumab and ipilimumab compared to nivolumab monotherapy in advanced unresectable cancers : a systematic review and meta analysis of randomized controlled trials

Year: 2026
Type: article
Abstract: Advanced unresectable malignancies are associated with significant global morbidity and mortality. While immune checkpoint inhibitors have revolutionized treatment, the optimal use of dual-agent blockade compared to monotherapy remains a subject of investigation. This systematic review and meta-analysis evaluates the efficacy and safety of nivolumab plus ipilimumab (I + N) versus nivolumab (N) monotherapy across diverse solid tumors, focusing on the impact of dosing regimens and PD-L1 expression. We searched PubMed, Scopus, Cochrane Library, and Web of Science through February 2026 for RCTs comparing I + N to N monotherapy in patients with advanced solid tumors. Primary outcomes included overall survival (OS), progression-free survival (PFS), objective response rate (ORR), and Grade ≥ 3 treatment-related adverse events (TRAEs). Data were pooled using random-effects models, with results reported as hazard ratios (HR) or risk ratios (RR). Sixteen studies were included. Compared with nivolumab monotherapy, the NIVO3 + IPI1 regimen significantly improved progression-free survival (HR 0.79, 95% CI 0.65–0.94), overall survival (HR 0.79, 95% CI 0.70–0.90), and objective response rate (RR 1.19, 95% CI 1.07–1.33). However, combination therapy was associated with increased grade ≥ 3 treatment-related adverse events (TRAEs) (RR 1.41, 95% CI 1.19–1.67), treatment discontinuation (RR 2.64, 95% CI 2.03–3.44), whereas the increase in treatment-related mortality was not statistically significant (RR 2.55, 95% CI 0.93–6.96). Compared with nivolumab monotherapy, the NIVO1 + IPI3 regimen demonstrated a significantly higher objective response rate (RR 1.49, 95% CI 1.20–1.84) but was also associated with increased grade ≥ 3 TRSAEs (RR 3.43, 95% CI 1.84–6.38). The predictive value of PD-L1 expression was heterogeneous across tumor types. Stronger associations between PD-L1 positivity and improved efficacy were observed in urothelial, esophagogastric, and mesothelioma cohorts, whereas clinically meaningful activity regardless of PD-L1 status was reported in melanoma, NSCLC, SCLC, and colorectal cancer. Conclusion: Dual checkpoint blockade improves efficacy outcomes across advanced solid tumors but at the cost of substantially increased toxicity, with PD-L1 status showing inconsistent predictive value across tumor types.
Source: BMC Cancer
Language: English
Subfield: Oncology
Field: Medicine
Open Access status: gold
Estimated APC paid: $3,390
OpenAlex ID: W7234783578
FWCI:
Cites:
Cited by:
Related to: 10